Clobetasol 0.05% Foam 100gm

• Burning
• Stinging
• Itching
• Dryness
• Folliculitis
• Hypertrichosis
• Acneiform eruptions
• Hypopigmentation
• Perioral dermatitis
• Allergic contact dermatitis
• Maceration of the skin
• Secondary infection
• Skin atrophy
• Striae
• Miliaria
• Signs of HPA axis suppression (fatigue, weakness, nausea, vomiting, hypotension)
• Signs of Cushing's syndrome (central obesity, moon face, buffalo hump, striae, easy bruising)

Clobetasol propionate is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown teratogenic effects with systemically administered corticosteroids. Clobetasol foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid large areas, prolonged use, or occlusive dressings.

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are excreted into breast milk in quantities not likely to have a deleterious effect on the infant. However, caution should be exercised when clobetasol foam is administered to a nursing woman. Avoid applying to the breast area to prevent direct infant exposure.

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Use in children under 12 years of age is not recommended. If used in adolescents 12 years and older, use with extreme caution, for the shortest duration possible, and monitor for signs of systemic toxicity and growth retardation.

Clinical studies of clobetasol propionate foam did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Elderly patients may have thinner skin, increasing susceptibility to local adverse effects like atrophy and purpura.

• Clobetasol propionate foam is a super-high potency topical corticosteroid; use it sparingly and for short durations (typically no more than 2 consecutive weeks).
• Limit total weekly application to 50 grams to minimize the risk of systemic absorption and HPA axis suppression.
• The foam formulation is often preferred for hairy areas or large surface areas due to its ease of spread and rapid absorption.
• Advise patients to apply the foam to a clean, dry surface (e.g., a saucer or cotton swab) and then transfer it to the skin, as it melts quickly on warm skin.
• Educate patients on the signs of local adverse effects (skin thinning, striae, telangiectasias) and systemic effects (e.g., weight gain, fatigue) and to report them promptly.
• Avoid use on the face, groin, or axillae unless specifically directed by a dermatologist, due to increased risk of skin atrophy and other side effects in these sensitive areas.
• Re-evaluate the patient if no improvement is seen after 2 weeks of treatment.

• Other topical corticosteroids (e.g., betamethasone, fluocinonide, triamcinolone, hydrocortisone) of varying potencies.
• Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) for atopic dermatitis, especially on sensitive areas.
• Vitamin D analogs (e.g., calcipotriene) for psoriasis.
• Retinoids (e.g., tazarotene) for psoriasis.
• Systemic therapies (e.g., biologics, methotrexate, cyclosporine) for severe, widespread, or refractory dermatoses.
• Phototherapy (UVB, PUVA) for psoriasis and severe eczema.